$599

ATTD 2026 Key Press Releases (March 12)

On the second day of ATTD 2026, three cardiometabolic-related news items have been observed: Lilly issued a public warning letter regarding the risk of compounded tirzepatide (view press release); Breakthrough T1D released a statement on cadaver donor islet cells and the ISLET Act (view press release); and Abbott shared results from its FreeDM2 study comparing Libre vs. SMBG in T2DM basal patients (view press release). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here